タンパク質治療薬の世界市場 - 世界の産業規模、シェア、動向、機会、予測、2018年～2028年、タンパク質機能別、製品タイプ別、地域別、競合

世界のタンパク質治療薬市場は、2022年に2,712億6,000万米ドルと評価され、2028年までのCAGRは6.80%で、予測期間中に目覚ましい成長を遂げると予測されています。

タンパク質治療薬とは、疾患の診断、予防、治療のための治療薬としてタンパク質やペプチドを利用する医療処置の一群を指します。これらの治療用タンパク質は、天然に存在するタンパク質、遺伝子操作されたタンパク質、合成ペプチドです。タンパク質治療薬は現代医学の基礎となっており、様々な病状を管理するための標的を絞った特異性の高いアプローチを提供しています。タンパク質治療薬は、組換えDNA技術、細胞培養、バイオプロセスなど、さまざまな方法で製造することができます。これらの方法は、純粋で一貫性のあるタンパク質製品の生産を保証します。タンパク質治療薬の主な利点の一つは、その高い特異性です。特定の分子や受容体を標的として設計できるため、標的外への影響を最小限に抑え、従来の低分子医薬品に比べて副作用を軽減することができます。タンパク質の生産と精製プロセスにおける継続的な技術革新は、製造コストを削減し、タンパク質治療薬の品質と安全性を向上させました。

抗体薬物複合体、二重特異性抗体、融合タンパク質など、タンパク質工学における絶え間ない技術革新は、タンパク質ベースの医薬品の治療能力を拡大しています。免疫チェックポイント阻害剤やCAR-T細胞療法などの免疫療法は、がんや自己免疫疾患の治療で普及しつつあり、市場の成長を後押ししています。世界の高齢化により、加齢に関連した疾患の有病率が上昇し、タンパク質治療薬の患者数が増加しています。生物製剤の類似品であるが同一ではないバイオシミラーの成長は競争を強化し、患者に費用対効果の高い治療選択肢を提供しています。ゲノミクスとバイオマーカー探索の進歩は個別化医療のアプローチを促進し、個々の患者のプロファイルに合わせたタンパク質治療薬の開発につながっています。新興諸国では、ヘルスケア支出の増加、医療へのアクセスの向上、先進治療への需要の高まりが見られ、これらの地域における市場拡大の原動力となっています。

主な市場促進要因

タンパク質工学の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のタンパク質治療薬市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • タンパク質機能別（酵素・調節薬、タンパク質診断薬、ワクチン）
  • 製品タイプ別（血液凝固因子、エリスロポエチン、卵胞刺激ホルモン、G-CSF、インスリン、インターフェロン、モノクローナル抗体）
  • 企業別（2022年）
• 市場マップ

第6章 アジア太平洋のタンパク質治療薬市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タンパク質機能別
  • 製品タイプ別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のタンパク質治療薬市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • タンパク質機能別
  • 製品タイプ別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のタンパク質治療薬市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タンパク質機能別
  • 製品タイプ別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のタンパク質治療薬市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タンパク質機能別
  • 製品タイプ別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのタンパク質治療薬市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タンパク質機能別
  • 製品タイプ別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のタンパク質治療薬市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

• Amgen Inc.
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Eli Lilly and Company.
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• F. Hoffmann-La Roche Ltd
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Johnson & Johnson Services, Inc.
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Merck KGaA
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Pfizer Inc.
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• AstraZeneca Plc.
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Teva Pharmaceutical Industries Ltd
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• AbbVie Inc.
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Bristol-Myers Squibb Company
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析

第17章 戦略的提言

第18章 調査会社・免責事項

Global Protein Therapeutics Market has valued at USD 271.26 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.80% through 2028. Protein therapeutics refers to a class of medical treatments that utilize proteins or peptides as therapeutic agents to diagnose, prevent, or treat diseases. These therapeutic proteins can be naturally occurring proteins, genetically engineered proteins, or synthetic peptides. Protein therapeutics have become a fundamental part of modern medicine, offering targeted and highly specific approaches to managing various medical conditions. Protein therapeutics can be produced through various methods, including recombinant DNA technology, cell culture, and bioprocessing. These methods ensure the production of pure and consistent protein products. One of the key advantages of protein therapeutics is their high specificity. They can be designed to target specific molecules or receptors, minimizing off-target effects, and reducing side effects compared to traditional small-molecule drugs. Continued technological innovations in protein production and purification processes were reducing manufacturing costs and improving the quality and safety of protein therapeutics.

Continuous innovations in protein engineering, including antibody-drug conjugates, bispecific antibodies, and fusion proteins, were expanding the therapeutic capabilities of protein-based drugs. Immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, were gaining traction in the treatment of cancer and autoimmune diseases, propelling market growth. The aging global population was leading to an increased prevalence of age-related diseases, creating a larger patient pool for protein therapeutics. The growth of biosimilars, which are similar but not identical versions of biologics, was enhancing competition and providing cost-effective treatment options for patients. Advances in genomics and biomarker discovery were promoting personalized medicine approaches, leading to the development of protein therapeutics tailored to individual patient profiles. Developing countries were experiencing increased healthcare expenditure, better access to healthcare, and a growing demand for advanced therapies, driving market expansion in these regions.

Key Market Drivers

Advancements in Protein Engineering

Directed evolution is a powerful technique that mimics the process of natural selection to improve the properties of proteins. It involves generating a library of protein variants, selecting those with desired traits, and then iteratively refining them through multiple rounds of mutation and selection. Directed evolution has been used to enhance enzyme activity, stability, and specificity for industrial and therapeutic applications. Computational methods, such as molecular modeling and structural analysis, enable scientists to predict how changes in a protein's amino acid sequence will impact its structure and function. Rational protein design allows for the custom engineering of proteins with specific properties, including enhanced binding affinity or altered catalytic activity. Antibody engineering techniques have led to the development of highly specialized monoclonal antibodies for targeted therapies. This includes the creation of bispecific antibodies that can simultaneously bind two different targets, as well as antibody-drug conjugates (ADCs) that deliver cytotoxic drugs to cancer cells. Fusion proteins are created by combining two or more protein domains or sequences to create multifunctional molecules. These fusion proteins can have enhanced stability, solubility, and therapeutic properties. For example, some fusion proteins combine the Fc region of an antibody with another protein to extend its half-life in the body.

Synthetic biology techniques enable the creation of entirely synthetic proteins and protein assemblies with designed functions. This field has applications in creating new biocatalysts, biosensors, and drug delivery systems. Protein-Drug Conjugates (PDCs) are designed to deliver cytotoxic drugs directly to target cells by attaching them to specific proteins or antibodies. This approach minimizes damage to healthy tissues and improves the therapeutic index of cancer treatments. Protein engineering plays a crucial role in the design and development of vaccines. Scientists can engineer viral proteins or antigenic regions to elicit a more potent and specific immune response while reducing potential side effects. Technologies like CRISPR-Cas9 have been adapted for protein engineering, allowing for precise modifications of genes encoding proteins. This enables the creation of designer proteins with desired properties. Phage display is a technique used to discover and engineer new proteins with specific binding properties. It involves displaying a library of protein variants on the surface of bacteriophages (viruses that infect bacteria) and selecting those that bind to a target of interest. Advancements in understanding protein folding kinetics and thermodynamics have improved our ability to design proteins with stable and predictable structures, which is essential for their function. This factor will help in the development of the Global Protein Therapeutics Market.

Rising Aging Population

With aging comes a higher risk of developing age-related and chronic diseases such as cancer, diabetes, Alzheimer's disease, and cardiovascular disorders. Many of these conditions are treated with protein-based therapeutics, including monoclonal antibodies, cytokines, and growth factors. Older adults often have multiple chronic conditions that require ongoing treatment. Protein therapeutics can provide effective management and control of these conditions, improving the quality of life for aging individuals. The immune system tends to weaken with age, making older adults more susceptible to infections and less responsive to traditional vaccines. Protein-based vaccines and immunotherapies, such as monoclonal antibodies, can help bolster immunity and protect against diseases.

Cancer incidence increases with age, and many targeted therapies for cancer are based on monoclonal antibodies and other protein therapeutics. These therapies can provide better outcomes and reduced side effects compared to traditional treatments. Age-related macular degeneration (AMD) and diabetic retinopathy are more common in older adults. Protein therapeutics, like anti-VEGF antibodies, have become a standard of care for treating these eye conditions. As people age, the risk of osteoporosis and fractures increases. Protein therapeutics like parathyroid hormone analogs are used to improve bone density and reduce the risk of fractures in older adults. Age is a significant risk factor for neurodegenerative diseases like Alzheimer's and Parkinson's disease. Protein-based therapies are being developed to target the underlying mechanisms of these conditions. Some age-related health issues, such as hormonal imbalances, can be managed with protein-based hormone replacement therapies. Older adults may experience delayed wound healing and tissue repair. Growth factors and cytokines, which are protein-based therapeutics, can aid in these processes. Improved healthcare and medical advancements have led to longer life expectancy. As people live longer, they may require ongoing medical treatment and interventions that include protein-based therapies. This factor will pace up the demand of the Global Protein Therapeutics Market.

Growing Immunotherapy

Immunotherapy has revolutionized the treatment of cancer. Monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapies, which are all protein-based immunotherapies, have shown remarkable efficacy in certain cancer types. They work by enhancing the immune system's ability to identify and target cancer cells. The success of these therapies has significantly increased the demand for protein-based treatments in oncology. Immunotherapy is not limited to cancer treatment. It is also being explored for the treatment of autoimmune diseases, infectious diseases, and other conditions. As research expands into these areas, it creates opportunities for new protein therapeutics to be developed and commercialized. Many immunotherapies are tailored to individual patients based on their specific immune profiles and the characteristics of their diseases. This personalized approach to treatment is driving the development of customized protein therapeutics, which can be more effective and less toxic than one-size-fits-all treatments. Combinations of different immunotherapies or immunotherapy with other forms of treatment, such as chemotherapy or radiation therapy, are being explored to enhance treatment efficacy. These combinations often involve protein-based therapeutics, further increasing their demand.

The success of immunotherapies has led to the development of biosimilars, which are similar but not identical versions of originator biologics. Biosimilars offer more affordable options for patients and healthcare systems while driving competition in the market. The regulatory landscape for immunotherapies has evolved to accommodate their unique mechanisms and patient populations. Regulatory approvals have facilitated the market entry of protein-based immunotherapies. The continued growth of clinical trials in immunotherapy research has driven the demand for protein therapeutics. Pharmaceutical companies and research institutions are investing heavily in developing and testing new immunotherapies. Immunotherapies have been adopted globally, increasing their accessibility and market reach. Emerging markets are also starting to play a significant role in driving demand for protein therapeutics, including immunotherapies. The success of immunotherapies has encouraged pharmaceutical and biotechnology companies to invest in R&D for new protein therapeutics. This investment has resulted in a robust pipeline of immunotherapies in various stages of development. Patients with conditions like cancer are increasingly seeking immunotherapy as a treatment option due to its potential for durable responses and fewer side effects compared to traditional treatments. This factor will accelerate the demand of the Global Protein Therapeutics Market.

Key Market Challenges

Manufacturing Complexities

Proteins are inherently complex molecules with precise three-dimensional structures. The manufacturing process must ensure the correct folding, post-translational modifications (e.g., glycosylation), and assembly of proteins to maintain their therapeutic efficacy. Protein therapeutics are often produced using genetically engineered cell lines, such as Chinese hamster ovary (CHO) cells or human cell lines. Developing stable and high-yielding cell lines is a time-consuming and intricate process. Upstream processing involves cell culture, where cells are grown in bioreactors and fed with nutrients to produce therapeutic protein. Maintaining optimal conditions for cell growth and protein expression is challenging and requires precise control of variables such as temperature, pH, and nutrient supply. Downstream processing involves the purification and isolation of the therapeutic protein from the cell culture. This step includes multiple chromatography and filtration steps to remove impurities, ensuring the final product's purity and safety. Stringent quality control measures are essential to verify the identity, purity, and potency of protein therapeutics. Analytical techniques must be highly sensitive and specific to detect and quantify impurities or variants. Transitioning from small-scale laboratory production to large-scale manufacturing presents technical challenges. Maintaining product consistency and quality on larger scales is critical. Protein therapeutics are subject to rigorous regulatory scrutiny. Manufacturers must adhere to good manufacturing practices (GMP) and meet stringent regulatory requirements, which can vary by region and country.

Product Pricing and Access

Developing protein-based therapeutics is a costly and resource-intensive process. This includes research and development, preclinical and clinical trials, regulatory compliance, and manufacturing scale-up. These expenses are often factored into the pricing of the final products. The production of protein therapeutics involves complex bioprocessing techniques, stringent quality control, and the use of specialized facilities. All these factors contribute to high manufacturing costs, which can impact product pricing. Regulatory agencies like the FDA and EMA have strict quality and safety standards for biologics and protein therapeutics. Complying with these regulations necessitates extensive testing and documentation, which adds to development costs. Companies invest heavily in research and development, and they often rely on patent protections to recoup their investments. This can lead to monopolies and high prices for branded protein therapeutics. Many protein therapeutics have limited competition, especially for rare diseases or conditions with a small patient population. This lack of competition can result in higher prices. While biosimilars offer the potential for cost savings, the development and regulatory approval of biosimilars can be time-consuming and expensive. Consequently, biosimilars may not always lead to substantial price reductions. Variations in healthcare reimbursement policies among countries and regions can impact patients' ability to access expensive protein therapeutics. In some cases, insurance coverage may be limited, requiring patients to bear a significant financial burden.

Key Market Trends

Biologics Dominance

Biologics, which include protein-based therapeutics such as monoclonal antibodies, enzymes, and vaccines, have gained prominence in the pharmaceutical industry. These biologics are derived from living organisms or cells, in contrast to small-molecule drugs that are chemically synthesized. Biologics are known for their high specificity and efficacy. They can be designed to target precise molecules or pathways involved in diseases, resulting in reduced off-target effects and enhanced therapeutic outcomes. The development and approval of monoclonal antibodies and other biologics for cancer immunotherapy have been a major driver of this trend. Immune checkpoint inhibitors, CAR-T cell therapies, and targeted therapies have revolutionized cancer treatment. Biologics have also played a critical role in the treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis. Monoclonal antibodies that modulate immune responses have been instrumental in managing these conditions. Biologics are used in the development of vaccines and antiviral therapies. The COVID-19 pandemic has highlighted the importance of biology in responding to global health crises. Biologics offer opportunities for personalized medicine approaches. They can be customized to match the genetic or disease profiles of individual patients, potentially improving treatment outcomes. The emergence of biosimilars, which are similar but not identical versions of originator biologics, has increased competition and provided more affordable options for patients. Biosimilars are helping to expand access to biologic treatments.

Segmental Insights

Protein Function Insights

In 2022, the Global Protein Therapeutics Market largest share was held by Vaccines segment and is predicted to continue expanding over the coming years. Protein therapeutics generally involve the use of proteins, such as monoclonal antibodies or recombinant proteins, for therapeutic purposes. Many vaccines are made using proteins as antigens. These antigens can be proteins or protein subunits derived from the target pathogen. For example, some COVID-19 vaccines use the spike protein of the SARS-CoV-2 virus as the antigen to trigger an immune response. When a vaccine is administered, the immune system recognizes the foreign antigen as a potential threat and mounts an immune response. This involves the production of antibodies and the activation of immune cells, such as T cells, that can recognize and destroy the pathogen. Vaccines have had a profound impact on global public health by preventing countless cases of infectious diseases, reducing mortality rates, and even leading to the eradication of some diseases (e.g., smallpox). They are essential tools in combating epidemics and pandemics.

Product Type Insights

In 2022, the Global Protein Therapeutics Market largest share was held by Monoclonal Antibodies segment in the forecast period and is predicted to continue expanding over the coming years. Monoclonal antibodies have demonstrated remarkable therapeutic efficacy in treating a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. They target specific antigens with high precision, reducing the risk of off-target effects. Monoclonal antibodies are versatile and can be designed to target various disease-related proteins and receptors. This versatility has led to their use in a broad spectrum of medical conditions. Monoclonal antibodies have a longer track record of successful development and clinical use compared to other types of protein therapeutics. This history of success has built confidence in their therapeutic potential. Immunotherapy, which includes the use of monoclonal antibodies, has gained prominence in cancer treatment. Drugs like checkpoint inhibitors (e.g., PD-1 and CTLA-4 inhibitors) and CAR-T cell therapies, which incorporate mAbs, have revolutionized cancer care. The biosimilars market for monoclonal antibodies has been growing rapidly. As patents for some originator mAbs expire, biosimilar versions offer more affordable treatment options, increasing accessibility for patients.

Regional Insights

The North America region dominates the Global Protein Therapeutics Market in 2022. North America, particularly the United States and Canada, has a highly developed healthcare infrastructure. This includes world-renowned research institutions, academic medical centers, and a robust pharmaceutical industry that fosters innovation and the development of protein therapeutics. North America has a robust R&D ecosystem that includes government agencies, private research organizations, and biotechnology companies. Funding from both public and private sources supports cutting-edge research in biotechnology and protein therapeutics. Many of the world's largest pharmaceutical and biotechnology companies are headquartered in North America. These companies have the resources and expertise to invest in protein therapeutics research, development, and commercialization. North America attracts a significant number of clinical trials for protein therapeutics. Regulatory agencies like the U.S. Food and Drug Administration (FDA) provide a clear regulatory pathway for drug approvals, making it an attractive region for conducting clinical research.

Key Market Players

• Amgen Inc.

• Eli Lilly and Company.

• F. Hoffmann-La Roche Ltd.

• Johnson & Johnson Services, Inc

• Merck KGaA

• Pfizer Inc

• AstraZeneca Plc.

• Teva Pharmaceutical Industries Ltd

• Bristol-Myers Squibb Company

• AbbVie Inc.

Report Scope:

In this report, the Global Protein Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Therapeutics Market, By Protein Function:

• Enzymatic & Regulatory
• Protein Diagnostics
• Vaccines

Protein Therapeutics Market, By Product Type:

• Blood Clotting Factor
• Erythropoietin
• Follicle Stimulating Hormone
• G-CSF
• Insulin
• Interferons
• Monoclonal Antibodies

Global Protein Therapeutics Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Protein Therapeutics Market.

Available Customizations:

• Global Protein Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Protein Function (Enzymatic & Regulatory, Protein Diagnostics, Vaccines)
  • 5.2.2. By Product Type (Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies)
  • 5.2.3. By Company (2022)
• 5.3. Market Map

6. Asia Pacific Protein Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Protein Function
  • 6.2.2. By Product Type
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Protein Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Protein Function
      • 6.3.1.2.2. By Product Type
  • 6.3.2. India Protein Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Protein Function
      • 6.3.2.2.2. By Product Type
  • 6.3.3. Australia Protein Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Protein Function
      • 6.3.3.2.2. By Product Type
  • 6.3.4. Japan Protein Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Protein Function
      • 6.3.4.2.2. By Product Type
  • 6.3.5. South Korea Protein Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Protein Function
      • 6.3.5.2.2. By Product Type

7. Europe Protein Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Protein Function
  • 7.2.2. By Product Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Protein Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Protein Function
      • 7.3.1.2.2. By Product Type
  • 7.3.2. Germany Protein Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Protein Function
      • 7.3.2.2.2. By Product Type
  • 7.3.3. Spain Protein Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Protein Function
      • 7.3.3.2.2. By Product Type
  • 7.3.4. Italy Protein Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Protein Function
      • 7.3.4.2.2. By Product Type
  • 7.3.5. United Kingdom Protein Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Protein Function
      • 7.3.5.2.2. By Product Type

8. North America Protein Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Protein Function
  • 8.2.2. By Product Type
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Protein Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Protein Function
      • 8.3.1.2.2. By Product Type
  • 8.3.2. Mexico Protein Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Protein Function
      • 8.3.2.2.2. By Product Type
  • 8.3.3. Canada Protein Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Protein Function
      • 8.3.3.2.2. By Product Type

9. South America Protein Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Protein Function
  • 9.2.2. By Product Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Protein Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Protein Function
      • 9.3.1.2.2. By Product Type
  • 9.3.2. Argentina Protein Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Protein Function
      • 9.3.2.2.2. By Product Type
  • 9.3.3. Colombia Protein Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Protein Function
      • 9.3.3.2.2. By Product Type

10. Middle East and Africa Protein Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Protein Function
  • 10.2.2. By Product Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Protein Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Protein Function
      • 10.3.1.2.2. By Product Type
  • 10.3.2. Saudi Arabia Protein Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Protein Function
      • 10.3.2.2.2. By Product Type
  • 10.3.3. UAE Protein Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Protein Function
      • 10.3.3.2.2. By Product Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Protein Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Amgen Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Eli Lilly and Company.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. F. Hoffmann-La Roche Ltd
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Johnson & Johnson Services, Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Merck KGaA
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Pfizer Inc.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. AstraZeneca Plc.
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Teva Pharmaceutical Industries Ltd
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. AbbVie Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. Bristol-Myers Squibb Company
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer